drugset
drugset / Trial / NCT05094336

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

NCT05094336 ↗

Phase 1/2 Active not recruiting 329 enrolled Amgen
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.

Timeline

Start
2022-02-01
Primary completion
2026-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Anvumetostat Unknown — Oral
Background Docetaxel Small molecule — Intravenous

Indications

No indication recorded.